Furthermore, a TRKB-specific inhibitor was developed (ANA-12), but has not been subjected to any clinical trials in cancer so far (Drilon et al., 2017; Ardini et al., 2016; Drilon et al., 2018; Burris et al., 2015). Here, NTRK2 is linked to cancer.